1. Home
  2. IKT vs ALXO Comparison

IKT vs ALXO Comparison

Compare IKT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.39

Market Cap

209.3M

Sector

Health Care

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$0.99

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
ALXO
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.3M
172.8M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
IKT
ALXO
Price
$1.39
$0.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
7
Target Price
★ $5.55
$4.60
AVG Volume (30 Days)
518.1K
★ 1.0M
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.76
26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$0.86
52 Week High
$2.61
$2.66

Technical Indicators

Market Signals
Indicator
IKT
ALXO
Relative Strength Index (RSI) 36.37 37.12
Support Level N/A $0.86
Resistance Level $1.71 $1.34
Average True Range (ATR) 0.12 0.14
MACD 0.00 -0.01
Stochastic Oscillator 2.82 12.27

Price Performance

Historical Comparison
IKT
ALXO

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: